{
  "resourceType" : "ValueSet",
  "id" : "2.16.840.1.113762.1.4.1234.50",
  "meta" : {
    "versionId" : "10",
    "lastUpdated" : "2022-01-06T01:02:20.000-05:00",
    "profile" : [
      "http://hl7.org/fhir/StructureDefinition/shareablevalueset",
      "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"
    ]
  },
  "extension" : [
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/valueset-author",
      "valueString" : "BEST System Author"
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate",
      "valueDate" : "2022-12-15"
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate",
      "valueDate" : "2022-01-06"
    }
  ],
  "url" : "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.50",
  "identifier" : [
    {
      "system" : "urn:ietf:rfc:3986",
      "value" : "urn:oid:2.16.840.1.113762.1.4.1234.50"
    }
  ],
  "version" : "20220106",
  "name" : "COVID19VaccineCodesForExposureIdentification",
  "title" : "COVID19 vaccine codes for exposure identification",
  "status" : "active",
  "experimental" : false,
  "date" : "2022-01-06T01:02:20-05:00",
  "publisher" : "BEST System Steward",
  "jurisdiction" : [
    {
      "extension" : [
        {
          "url" : "http://hl7.org/fhir/StructureDefinition/data-absent-reason",
          "valueString" : "UNKNOWN"
        }
      ]
    }
  ],
  "purpose" : "(Clinical Focus: COVID-19 vaccine codes for identification of potential biologics-related adverse events.),(Data Element Scope: This value set may use a model element in the QDM category of Procedure/Intervention, Immunization, Medication, or Substance.),(Inclusion Criteria: COVID-19 vaccine codes, including CPT, RxNorm, and CVX.),(Exclusion Criteria: None)",
  "compose" : {
    "include" : [
      {
        "valueSet" : [
          "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.42"
        ]
      },
      {
        "valueSet" : [
          "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.44"
        ]
      },
      {
        "valueSet" : [
          "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.43"
        ]
      },
      {
        "valueSet" : [
          "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.75"
        ]
      }
    ]
  },
  "expansion" : {
    "identifier" : "urn:uuid:ea65d327-7698-49a0-9852-f64941670af0",
    "timestamp" : "2023-06-29T16:49:29-04:00",
    "total" : 28,
    "offset" : 0,
    "parameter" : [
      {
        "name" : "count",
        "valueInteger" : 1000
      },
      {
        "name" : "offset",
        "valueInteger" : 0
      }
    ],
    "contains" : [
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2023",
        "code" : "0001A",
        "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; first dose"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2023",
        "code" : "0002A",
        "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; second dose"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2023",
        "code" : "0003A",
        "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2023",
        "code" : "0011A",
        "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; first dose"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2023",
        "code" : "0012A",
        "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; second dose"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2023",
        "code" : "0013A",
        "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2023",
        "code" : "0031A",
        "display" : "Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5 mL dosage; single dose"
      },
      {
        "system" : "http://hl7.org/fhir/sid/cvx",
        "version" : "20230606",
        "code" : "207",
        "display" : "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose"
      },
      {
        "system" : "http://hl7.org/fhir/sid/cvx",
        "version" : "20230606",
        "code" : "208",
        "display" : "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose"
      },
      {
        "system" : "http://hl7.org/fhir/sid/cvx",
        "version" : "20230606",
        "code" : "210",
        "display" : "SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-ChAdOx1, preservative free, 0.5 mL"
      },
      {
        "system" : "http://hl7.org/fhir/sid/cvx",
        "version" : "20230606",
        "code" : "212",
        "display" : "SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL"
      },
      {
        "system" : "http://hl7.org/fhir/sid/cvx",
        "version" : "20230606",
        "code" : "213",
        "display" : "SARS-COV-2 (COVID-19) vaccine, UNSPECIFIED"
      },
      {
        "system" : "http://hl7.org/fhir/sid/cvx",
        "version" : "20230606",
        "code" : "217",
        "display" : "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose, tris-sucrose formulation"
      },
      {
        "system" : "http://hl7.org/fhir/sid/cvx",
        "version" : "20230606",
        "code" : "218",
        "display" : "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 10 mcg/0.2mL dose, tris-sucrose formulation"
      },
      {
        "system" : "http://hl7.org/fhir/sid/cvx",
        "version" : "20230606",
        "code" : "219",
        "display" : "SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 3 mcg/0.2mL dose, tris-sucrose formulation"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version" : "06052023",
        "code" : "2468235",
        "display" : "SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 0.1 MG/ML Injectable Suspension"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version" : "06052023",
        "code" : "2470234",
        "display" : "SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 0.2 MG/ML Injectable Suspension"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version" : "06052023",
        "code" : "2479835",
        "display" : "SARS-COV-2 (COVID-19) vaccine, vector - Ad26 100000000000 UNT/ML Injectable Suspension"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version" : "06052023",
        "code" : "2583743",
        "display" : "SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 0.05 MG/ML Injectable Suspension"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2023",
        "code" : "91300",
        "display" : "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted, for intramuscular use"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2023",
        "code" : "91301",
        "display" : "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage, for intramuscular use"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2023",
        "code" : "91303",
        "display" : "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5 mL dosage, for intramuscular use"
      },
      {
        "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
        "version" : "2023",
        "code" : "XW013S6",
        "display" : "Introduction of COVID-19 Vaccine Dose 1 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6"
      },
      {
        "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
        "version" : "2023",
        "code" : "XW013T6",
        "display" : "Introduction of COVID-19 Vaccine Dose 2 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6"
      },
      {
        "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
        "version" : "2023",
        "code" : "XW013U6",
        "display" : "Introduction of COVID-19 Vaccine into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6"
      },
      {
        "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
        "version" : "2023",
        "code" : "XW023S6",
        "display" : "Introduction of COVID-19 Vaccine Dose 1 into Muscle, Percutaneous Approach, New Technology Group 6"
      },
      {
        "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
        "version" : "2023",
        "code" : "XW023T6",
        "display" : "Introduction of COVID-19 Vaccine Dose 2 into Muscle, Percutaneous Approach, New Technology Group 6"
      },
      {
        "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
        "version" : "2023",
        "code" : "XW023U6",
        "display" : "Introduction of COVID-19 Vaccine into Muscle, Percutaneous Approach, New Technology Group 6"
      }
    ]
  }
}
